Your browser doesn't support javascript.
Post COVID-19 sequelae: A prospective observational study from Northern India.
Naik, Shivdas; Haldar, Soumendra Nath; Soneja, Manish; Mundadan, Netto George; Garg, Prerna; Mittal, Ankit; Desai, Devashish; Trilangi, Praveen Kumar; Chakraborty, Sayan; Begam, Nazneen Nahar; Bhattacharya, Bisakh; Maher, Ganesh; Mahishi, Niranjan; Rajanna, Chaithra; Kumar, Swasthi S; Arunan, Bharathi; Kirtana, J; Gupta, Ankesh; Patidar, Diksha; Kodan, Parul; Sethi, Prayas; Ray, Animesh; Jorwal, Pankaj; Kumar, Arvind; Nischal, Neeraj; Sinha, Sanjeev; Biswas, Ashutosh; Wig, Naveet.
  • Naik S; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Haldar SN; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Soneja M; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Mundadan NG; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Garg P; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Mittal A; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Desai D; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Trilangi PK; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Chakraborty S; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Begam NN; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Bhattacharya B; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Maher G; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Mahishi N; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Rajanna C; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Kumar SS; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Arunan B; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Kirtana J; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Gupta A; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Patidar D; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Kodan P; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Sethi P; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Ray A; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Jorwal P; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Kumar A; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Nischal N; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Sinha S; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Biswas A; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Wig N; Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Drug Discov Ther ; 15(5): 254-260, 2021 Nov 21.
Article in English | MEDLINE | ID: covidwho-1542928
ABSTRACT
Post COVID-19 sequelae are a constellation of symptoms often reported after recovering from COVID-19. There is a need to better understand the clinical spectrum and long-term course of this clinical entity. The aim of this study is to describe the clinical features and risk factors of post COVID-19 sequelae in the North Indian population. This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 and February 2021. Patients aged >18 years with laboratory-confirmed COVID-19 were recruited after at least two weeks of diagnosis, and details were captured. A total of 1234 patients were recruited and followed up for a median duration of 91 days (IQR 45-181 days). Among them, 495 (40.1%) had persistent symptoms post-discharge or recovery. In 223 (18.1%) patients, the symptoms resolved within four weeks; 150 (12.1%) patients had symptoms till 12 weeks, and 122 (9.9%) patients had symptoms beyond 12 weeks of diagnosis/symptom-onset of COVID-19. Most common symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), insomnia (1.4%), mood disturbances (0.48%) and anxiety (0.6%). Patients who were hospitalized were more likely to report fatigue as a feature of long COVID. Hypothyroidism (OR 4.13, 95% CI 2.2-7.6, p-value < 0.001) and hypoxia (SpO2 ≤ 93%) (OR 1.7, 95% CI 1.1-2.4, p-value 0.012) were identified as risk factors for long COVID sequelae. In conclusion, long COVID symptoms were common (22%), and 9.9% had the post COVID-19 syndrome. Myalgias, fatigue and dyspnoea were common symptoms. Patients with hypothyroidism and hypoxia during acute illness were at higher risk of long COVID.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Drug Discov Ther Year: 2021 Document Type: Article Affiliation country: Ddt.2021.01093

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Drug Discov Ther Year: 2021 Document Type: Article Affiliation country: Ddt.2021.01093